(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
30 June 2005 (30.06.2005)

PCT

(10) International Publication Number
WO 2005/058327 A1

(51) International Patent Classification[7]: A61K 31/5383, C07D 498/16, 519/00, 471/06, A61K 31/546, 31/403, A61P 25/04

(21) International Application Number:
PCT/EP2004/053421

(22) International Filing Date:
13 December 2004 (13.12.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/530,528	17 December 2003 (17.12.2003)	US
03104768.1	17 December 2003 (17.12.2003)	EP

(71) Applicant *(for all designated States except US)*: AKZO NOBEL N.V. [NL/NL]; Velperweg 76, NL-6824 BM Arnhem (NL).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: ADAM-WORRALL, Julia [GB/GB]; c/o: Organon Laboratories Ltd., New Edinburgh Road, Newhouse, Lanrakshire ML1 5SH (GB).

(74) Agent: VAN WEZENBEEK, P., M., G., F.; P.O. Box 20, NL-5340 BH Oss (NL).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TRICYCLIC 1-[(3-INDOL-3-YL)CARBONYL] PIPERAZINE DERIVATIVES AS CANNABINOID CB1 RECEPTOR AGONISTS



(I)

(57) Abstract: The invention relates to tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivative having the general Formula (I) wherein X is CH_2, O or S; R represents 1-3 substituents independently selected from H, (C_{1-4})alkyl, (C_{1-4})alkyloxy and halogen; R_1 is (C_{5-8})cycloalkyl; R_2 is H or (C_{1-4})alkyl; R_3, R_3', R_4' R_4', R_5, R_5' and R_6' are independently hydrogen or (C_{1-4})-alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen; R_6 is hydrogen or (C_{1-4})alkyl, optionally substituted with (C_{1-4})alkyloxy, OH or halogen; or R_6 forms together with R_7a 4-7 membered saturated heterocyclic ring, optionally containing a further heteroatom selected from O and S; R_7 forms together with R_6 a 4-7 membered saturated heterocydic ring, optionally containing a further heteroatom selected from O and S; or R_7 is H, (C_{1-4})alkyl or (C_{3-5})cycloalkyl, the alkyl groups being optionally substituted with OH, halogen or (C_{1-4})alkyloxy; or a pharmaceutically acceptable salt thereof. The invention also relates to pharmaceutical compositions comprising said tricyclic 1-[(indol-3-yl)carbonyl]piperazine derivatives, and to the use of these derivatives in the treatment of pain, such as peri-operative pain, chronic pain neuropathic pain, cancer pain, and pain and spasticity associated with multiple sclerosis.

WO 2005/058327 A1